openPR Logo
Press release

Hetero Healthcare set to supply Covid-19 drug Remdesivir under brand name COVIFOR.

06-25-2020 09:33 AM CET | Health & Medicine

Press release from: Hetero Healthcare Limited

Hetero’s group company ‘Hetero Healthcare Limited’ is all set to supply 20,000 vials of Covifor (Remdesivir)across the country.

Following the approval of ‘COVIFOR’, the generic of Remdesivir by DCGI, Hetero Healthcare Limited, a group company of Heterois set to deliver the first set of 20,000 vials in two equal lots of 10,000 each, one of which, will be immediately supplied to Hyderabad, Delhi, Gujarat, Tamil Nadu, Mumbai and other parts of Maharashtra; while the other lot will be supplied to Kolkata, Indore, Bhopal, Lucknow, Patna, Bhubaneshwar, Ranchi, Vijayawada, Cochin, Trivandrum and Goa within a week’s time, in order to meet the emergency requirements.

Mr. M. Srinivasa Reddy, Managing Director, Hetero Healthcare Limited said: “The launch of COVIFOR in India is a significant milestone for all of us. Hetero Healthcare has always been at the forefront in addressing public health emergencies. Through Covifor, we hope to reduce the treatment time of a patient in a hospital, thereby reducing the increasing pressure on the medical infrastructure, overburdened currently due to accelerating COVID-19 infection rates. We are working closely with the Government and Medical Community to make ‘Covifor’ quickly accessible to both public and private healthcare settings across the country.”
Covifor is the first generic brand of Remdesivir which is indicated for the treatment of COVID-19 patients in adults and children, hospitalized with severe symptoms of the disease. The drug is available in 100 mg vial (Injectable). It needs to be administered intravenously in a hospital, critical care setting, under the supervision of a registered medical practitioner. Covifor is anticipated to play a significant role in bringing down the mortality rates caused by COVID-19, given its proven positive clinical outcomes.

For more information, visit http://www.heterohealthcare.com/covifor-100mg-injection

For Enquiries
• Hospitals can place their orders by sending an e-mail to COVIFOR@heterohealthcare.com
• Patients can reach out to Hetero Healthcare Team either through toll-free no.: 1800 1034 696 or through WhatsApp on +91 9320985814

Hetero Healthcare Limited
S.no: 80-84, Melange Towers, Patrika Nagar, Madhapur, Hyderabad, Telangana 500081, India
Phone: +91 40 4047 3535

Established in 1994, Hetero Healthcare Limited is a group company of Hetero which is engaged in the marketing and distribution of medicines in the Indian market. The company has a strong presence in India with 11 specialized marketing divisions and has been a market leader in ARV, Oncology, anti-flu anti-bacterial. With the team of 3200+ field force, Hetero Healthcare caters to medical practitioners in over 400 territories across India.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hetero Healthcare set to supply Covid-19 drug Remdesivir under brand name COVIFOR. here

News-ID: 2080109 • Views:

More Releases from Hetero Healthcare Limited

Favivir by Hetero Healthcare for Mild to Moderate Covid-19 is Available Now
Favivir by Hetero Healthcare for Mild to Moderate Covid-19 is Available Now
About FAVIVIR FAVIVIR is the brand name of the generic Favipiravir (200 mg) drug which acts against different forms of influenza viruses including those that do not work on other medications. Favipiravir is a novel antiviral drug, which selectively and effectively inhibits influenza RNA-dependent polymerase (RdRP) and many other RNA viruses. FAVIVIR increases adherence to care for a large portion of the Covid-19 patient population, which typically has mild to moderate

More Releases for Covifor

India Generic Drugs Market Growth, Size, Share, Industry Report and Forecast 202 …
India generic drugs market is estimated to grow at a CAGR of nearly 9.5% during the forecast period. A significant rise in the incidences of chronic diseases is driving the demand for generic drugs in the country. The National Cancer Registry Programme estimates that there will be 13.9 lakh new cancer incidences reported in India in 2020, which is expected to rise to 15.7 lakh by 2025. This leads to
Asia-Pacific Generic Drugs Market Size, Industry Trends, Share and Forecast 2020 …
Asia-Pacific generic drugs market is estimated to grow at a CAGR of nearly 8.0% during the forecast period. A significant rise in the prevalence of chronic diseases is the major factor accelerating the demand for generic medicines in the region. As per the estimation by the World Health Organization (WHO), the number of new cancer incidences expected to be reported in china was nearly 4.6 million in 2020. Further, the
Asia-Pacific Generic Drugs Market 2021: Top Industry Players, Growth Report to 2 …
Asia-Pacific generic drugs market is estimated to grow at a CAGR of nearly 8.0% during the forecast period. A significant rise in the prevalence of chronic diseases is the major factor accelerating the demand for generic medicines in the region. As per the estimation by the World Health Organization (WHO), the number of new cancer incidences expected to be reported in china was nearly 4.6 million in 2020. Further, the
India Generic Drugs Market Size & Growth Analysis Report, 2020-2026
India generic drugs market is estimated to grow at a CAGR of nearly 9.5% during the forecast period. A significant rise in the incidences of chronic diseases is driving the demand for generic drugs in the country. The National Cancer Registry Programme estimates that there will be 13.9 lakh new cancer incidences reported in India in 2020, which is expected to rise to 15.7 lakh by 2025. This leads to
Promising Antidote for COVID-19: Covifor Drug Market 2020-2028 Soaring Demand wi …
Covifor (Remdesivir) Drug is an anti-viral drug available in vial (injectable) form which has to be administered intravenously in a hospital setting under the supervision of a healthcare practitioner. This drug assumed to be helpful in the treatment of COVID-19. The Global Covifor Drug Market report aims to provide an overview of the market with detailed segmentation by organization size, business, industry vertical, and geography. The Global Covifor Drug Market